Lantheus shares are trading lower by 5.4% during Monday's session. The company announced a $350 million acquisition.

Lantheus CEO Brian Markison commented, “This partnership is an important step forward in our purpose to advance our best-in-class radiopharmaceutical therapies. Radiopharm’s deep expertise and ...

Lantheus CEO Brian Markison said the company was pleased to increase its holding in Radiopharm, while continuing to work jointly in Australia on the clinical development of radiopharmaceutical assets.

Lantheus CEO Brian Markison said the company was pleased to increase its holding in Radiopharm, while continuing to work jointly in Australia on the clinical development of radiopharmaceutical assets.

Lantheus CEO Brian Markison commented, “This partnership is an important step forward in our purpose to advance our best-in-class radiopharmaceutical therapies. Radiopharm’s deep expertise and ...

Lantheus Holdings Inc. (LNTH), a radiopharmaceutical-focused company, announced Monday a definitive agreement to acquire Life ...

Brian Markison, CEO of Lantheus, said the acquisition aligns with its strategy to drive long-term growth and value creation by investing in high-potential, complementary assets and R&D ...

We look forward to continuing this positive momentum going forward.” Lantheus CEO Brian Markison said: “We are pleased to increase our holding in Radiopharm, while continuing to work jointly ...

The placement of 133 million shares was completed at an issue price of A$0.060 per share, representing a 150% premium to the last traded price of RAD shares (A$0.024). Settlement is expected to occur ...